Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
No FDA status Not FDA-approved Compound Semaglutide Mechanism GLP-1 receptor agonist
This targeted approach makes it a more refined and potentially safer option for weight loss
A fifty-four-year-old woman experiencing paranoid delusions and violent outbursts, coupled with symptoms that her doctor diagnoses as multiple sclerosis
The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary
